ONC
HEALTHCAREBeiGene Ltd
$313.32+15.83 (+5.32%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ONC Today?
No stock-specific AI insight has been generated for ONC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$218.31$385.22
$313.32
Fundamentals
Market Cap$32.5B
P/E Ratio70.9
EPS$4.42
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume386K
Avg Volume (10D)—
Shares Outstanding94.9M
ONC News
20 articles- Earnings Beat: BeOne Medicines AG Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsYahoo Finance·May 8, 2026
- BeOne Medicines Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- BeOne Medicines Announces First Quarter 2026 Financial Results and Business UpdatesYahoo Finance·May 6, 2026
- Did FDA Fast-Track HER2 Regimen Just Shift BeOne Medicines' (ONC) Investment Narrative?Yahoo Finance·May 5, 2026
- AMD downgraded, Airbnb upgraded: Wall Street's top analyst callsYahoo Finance·May 4, 2026
- U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEAYahoo Finance·Apr 29, 2026
- BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6Yahoo Finance·Apr 22, 2026
- BeOne Medicines price target lowered to $411 from $412 at TruistYahoo Finance·Apr 9, 2026
- BeOne Medicines (ONC) Is Up 9.4% After FDA Orphan Status And New Analyst Coverage For Liver CancerYahoo Finance·Apr 6, 2026
- Wolfe Research Initiates Coverage of BeOne Medicines AG (ONC) with Outperform RatingYahoo Finance·Apr 4, 2026
- BeOne Medicines (ONC) Downgraded Despite Strong Oncology PortfolioYahoo Finance·Apr 2, 2026
- BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic ExpansionYahoo Finance·Mar 4, 2026
- BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma TreatmentYahoo Finance·Mar 1, 2026
- Is It Time To Reassess BeOne Medicines (ONC) After Strong Multi Year Share Price GainsYahoo Finance·Feb 26, 2026
- Here's What Key Metrics Tell Us About BeOne Medicines Ltd. - Sponsored ADR (ONC) Q4 EarningsYahoo Finance·Feb 26, 2026
- BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology LeadershipYahoo Finance·Feb 26, 2026
- BeOne Medicines to Present at Upcoming Investor ConferencesYahoo Finance·Feb 17, 2026
- Bernstein Remains a Buy on BeOne Medicines AG (ONC)Yahoo Finance·Feb 13, 2026
- BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26Yahoo Finance·Feb 11, 2026
- Should InSysBio Modeling Partnership Expansion Shape How Investors View BeOne Medicines’ (ONC) Oncology Strategy?Yahoo Finance·Feb 2, 2026
All 20 articles loaded
Price Data
Open$295.27
Previous Close$297.49
Day High$297.62
Day Low$291.66
52 Week High$385.22
52 Week Low$218.31
52-Week Range
$218.31$385.22
$313.32
Fundamentals
Market Cap$32.5B
P/E Ratio70.9
EPS$4.42
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume386K
Avg Volume (10D)—
Shares Outstanding94.9M
About BeiGene Ltd
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—